NCT00671671

Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus.

A Phase 1, Non- Randomized, Open Label, Sequential Group, Multicenter Study To Evaluate The Antiviral Activity Of Multiple Doses Of A Small Molecule Direct Antiviral Agent In Chronically Infected Hepatitis C Subjects.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Phase 1 study in HVC (Hepatitis C Virus) infected subjects to determine pharmacokinetics, safety and efficacy in subjects with no or inadequate response to prior treatment.

Conditions

• Hepatitis, Chronic
• Hepatitis C Virus

Interventions

Type	Name	Description
DRUG	Small Molecule Agent (PF-868554)	Study drug will be administered 700mg BID in the fed state for three days.
DRUG	Small Molecule Agent (PF-868554)	Study drug will be given 450mg BID for a duration of 10 days.

Timeline

• Start date: 2008-04-01
• Primary completion: 2008-12-01
• Completion: 2008-12-01
• First posted: 2008-05-05
• Last updated: 2014-01-14
• Results posted: 2014-01-14

Locations

1 site across 1 country: United States